Media Coverage

Though countless diagnostic developers struck it rich at the height of the COVID-19 pandemic, many of those that were relatively new to the testmaking game are now struggling to make up for lost sales as the spread of the virus slows down. Not so for established testing giants like Quest Diagnostics, which has seen its base business rebound in direct relation to dropping COVID-related earnings.

Stocks that traded heavily or had substantial price changes Thursday: Tesla Inc., down $14.76 to $207.28. The electric vehicle maker warned it could miss its target of 50% annual growth in deliveries this year. Quest Diagnostics Inc., up $8 to $134.66. The medical laboratory chain’s third-quarter earnings and revenue beat analysts’ forecasts.

Decode Health has announced a new phase of its collaboration with Quest Diagnostics. In earlier phases of the collaboration, the two parties developed RNA (transcriptome) sequencing capabilities.

Recent research shows more messaging about cancer screening is needed. This is because diagnoses of prostate and breast cancer remain significantly below pre-pandemic levels. While this may sound like good news, it's not. The lower figures are due to a reverberating trend stemming from the pandemic. Based on data from 1.1 million patients, a Quest Diagnostics' analysis found cancer diagnoses plummeted nearly 30% in the first months of the pandemic in 2020, when much of society and healthcare were shuttered.

Quest Diagnostics said it recently joined forces with a free H.O.P.E. Clinic in Plainfield operated by Rutgers University to help reduce health disparities in a community with a high percentage of uninsured adults by providing free lab services. Not only is this helping people with chronic conditions receive the treatments they need, but it also is helping to keep health care costs down by giving people an alternative to emergency departments.